Recently, the 2023 National Key Research and Development Program "Government Inter-Agency International Science and Technology Innovation Cooperation" project led by Neuboron has been approved and launched by the Ministry of Science and Technology. The National Key Research and Development Program represents the highest level of research and development projects in China. The successful approval of this project marks a new starting point for Neuboron's entry into the field of BNCT new drug innovation.
Since its establishment, Neuboron has undertaken or participated in 10 key scientific research projects, covering the development of BNCT system equipment, radiobiological research, treatment planning system development, radiation protection, dosimetry studies, and drug innovation. These efforts have accelerated the deep integration of "industry, academia, research, and medicine" in BNCT, providing momentum for the industrialization of BNCT.
Over the past decade, Neuboron has collaborated with a number of top universities, research institutes, and hospitals, including Nanjing University of Aeronautics and Astronautics, Xiamen Humanity Hospital, China Pharmaceutical University, Peking Union Medical College Hospital, Zhejiang University, Kyoto University, the Italian National Institute of Nuclear Physics, and the University of Pavia. Together, they have focused on breakthroughs in core technologies and accelerated the basic research and clinical translation of BNCT.
Additionally, Neuboron has deepened its cooperation with Nanjing University of Aeronautics and Astronautics in areas such as joint talent cultivation, collaborative research, and industrial development. This collaboration has catalyzed the integration of industry, academia, and research, unleashing more vitality.
In 2024, Neuboron will continue to focus on technological research and development, expand clinical applications, and promote the advancement of medical technology in China.
